Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function

Asymmetric bispecific antibodies are a rapidly expanding therapeutic antibody class, designed to recognize two different target epitopes concurrently to achieve novel functions not available with normal antibodies. Many therapeutic designs require antibodies with reduced or silenced effector functio...

Full description

Bibliographic Details
Main Authors: Eric Escobar-Cabrera, Paula Lario, Jason Baardsnes, Joseph Schrag, Yves Durocher, Surjit Dixit
Format: Article
Language:English
Published: MDPI AG 2017-05-01
Series:Antibodies
Subjects:
Online Access:http://www.mdpi.com/2073-4468/6/2/7
id doaj-be9716f33f7146518d70ed30b1763cf2
record_format Article
spelling doaj-be9716f33f7146518d70ed30b1763cf22020-11-24T22:23:53ZengMDPI AGAntibodies2073-44682017-05-0162710.3390/antib6020007antib6020007Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector FunctionEric Escobar-Cabrera0Paula Lario1Jason Baardsnes2Joseph Schrag3Yves Durocher4Surjit Dixit5Zymeworks Inc., 540-1385 West 8th Ave, Vancouver, BC V6H 3V9, CanadaZymeworks Inc., 540-1385 West 8th Ave, Vancouver, BC V6H 3V9, CanadaHuman Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave, Montreal, QC H4P 2R2, CanadaHuman Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave, Montreal, QC H4P 2R2, CanadaHuman Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave, Montreal, QC H4P 2R2, CanadaZymeworks Inc., 540-1385 West 8th Ave, Vancouver, BC V6H 3V9, CanadaAsymmetric bispecific antibodies are a rapidly expanding therapeutic antibody class, designed to recognize two different target epitopes concurrently to achieve novel functions not available with normal antibodies. Many therapeutic designs require antibodies with reduced or silenced effector function. Although many solutions have been described in the literature to knockout effector function, to date all of them have involved the use of a specific antibody subtype (e.g., IgG2 or IgG4), or symmetric mutations in the lower hinge or CH2 domain of traditional homodimeric monospecific antibodies. In the context of a heterodimeric Fc, we describe novel asymmetric Fc mutations with reduced or silenced effector function in this article. These heteromultimeric designs contain asymmetric charged mutations in the lower hinge and the CH2 domain of the Fc. Surface plasmon resonance showed that the designed mutations display much reduced binding to all of the Fc gamma receptors and C1q. Ex vivo ADCC and CDC assays showed a consistent reduction in activity. Differential scanning calorimetry showed increased thermal stability for some of the designs. Finally, the asymmetric nature of the introduced charged mutations allowed for separation of homodimeric impurities by ion exchange chromatography, providing, as an added benefit, a purification strategy for the production of bispecific antibodies with reduced or silenced effector function.http://www.mdpi.com/2073-4468/6/2/7Fc engineeringasymmetric bispecific antibodyion exchange chromatographyknock-out effector function
collection DOAJ
language English
format Article
sources DOAJ
author Eric Escobar-Cabrera
Paula Lario
Jason Baardsnes
Joseph Schrag
Yves Durocher
Surjit Dixit
spellingShingle Eric Escobar-Cabrera
Paula Lario
Jason Baardsnes
Joseph Schrag
Yves Durocher
Surjit Dixit
Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
Antibodies
Fc engineering
asymmetric bispecific antibody
ion exchange chromatography
knock-out effector function
author_facet Eric Escobar-Cabrera
Paula Lario
Jason Baardsnes
Joseph Schrag
Yves Durocher
Surjit Dixit
author_sort Eric Escobar-Cabrera
title Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
title_short Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
title_full Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
title_fullStr Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
title_full_unstemmed Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
title_sort asymmetric fc engineering for bispecific antibodies with reduced effector function
publisher MDPI AG
series Antibodies
issn 2073-4468
publishDate 2017-05-01
description Asymmetric bispecific antibodies are a rapidly expanding therapeutic antibody class, designed to recognize two different target epitopes concurrently to achieve novel functions not available with normal antibodies. Many therapeutic designs require antibodies with reduced or silenced effector function. Although many solutions have been described in the literature to knockout effector function, to date all of them have involved the use of a specific antibody subtype (e.g., IgG2 or IgG4), or symmetric mutations in the lower hinge or CH2 domain of traditional homodimeric monospecific antibodies. In the context of a heterodimeric Fc, we describe novel asymmetric Fc mutations with reduced or silenced effector function in this article. These heteromultimeric designs contain asymmetric charged mutations in the lower hinge and the CH2 domain of the Fc. Surface plasmon resonance showed that the designed mutations display much reduced binding to all of the Fc gamma receptors and C1q. Ex vivo ADCC and CDC assays showed a consistent reduction in activity. Differential scanning calorimetry showed increased thermal stability for some of the designs. Finally, the asymmetric nature of the introduced charged mutations allowed for separation of homodimeric impurities by ion exchange chromatography, providing, as an added benefit, a purification strategy for the production of bispecific antibodies with reduced or silenced effector function.
topic Fc engineering
asymmetric bispecific antibody
ion exchange chromatography
knock-out effector function
url http://www.mdpi.com/2073-4468/6/2/7
work_keys_str_mv AT ericescobarcabrera asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction
AT paulalario asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction
AT jasonbaardsnes asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction
AT josephschrag asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction
AT yvesdurocher asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction
AT surjitdixit asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction
_version_ 1725763557696471040